Current and Emerging Data on SGLT2 Inhibitors in Heart Failure

Published: 03 December 2019

  • Views:

    Views Icon 525

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

The opportunity for cardiovascular disease prevention in patients with type 2 diabetes mellitus (T2DM) has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE) including sodium-glucose co-transporter-2 (SGLT2) demonstrating robust reductions in heart failure (HF). Although the exact mechanisms of cardiovascular (CV) benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects.

Recent trials — including the recently presented DAPA-HF — have provided further insight into the effectiveness of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in the absence of T2DM.
 

EBAC Accreditation

This video is funded by an unrestricted educational grant from AstraZeneca.

Learning Objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data; differentiate the latest guideline updates for the treatment of T2D
  • Consider comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF)
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF
  • Assess the interrelationships linking diabetes, HF and CVD
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.

More from this programme

Part 1

SGLT2 in HF Now and the Future

1 session
SGLT2 in HF Now and the Future Watch now

Part 2

DAPA-HF Trial Design Rationale

1 session
DAPA-HF Trial Design Rationale Watch now

Part 3

SGLT2 beyond diabetes

1 session
SGLT2 beyond diabetes Watch now

Part 4

Guidelines, Recent Data & Future Practices

1 session
Guidelines, Recent Data & Future Practices Watch now

Part 5

DAPA-HF Trial

1 session
DAPA-HF Trial Watch now

Part 6

Discussion with the DAPA-HF Trialist

1 session
Discussion with the DAPA-HF Trialist Watch now

Faculty Biographies

Felipe Martínez

Felipe Martínez

Emeritus Professor of Medicine - Cordoba National University
Director - Instituto DAMIC-Fundación Rusculleda, Córdoba, Argentina
Fellow of the European Society of Cardiology (FESC)
Fellow of the American College of Cardiology (FACC)
Past President - International Society of Cardiovascular Pharmacology

Dr Felipe Martínez is on the Editorial Board of European Cardiology Review.

View full profile